Boston & Bedford, Massachusetts, August 3, 2026
Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement that will create one of the world’s leading radiopharmaceutical companies, combining Curium’s global theranostics portfolio, manufacturing capabilities and radioligand therapy pipeline with Lantheus’ established U.S. radiodiagnostics business. The strategic transaction is valued at up to $8.0 billion, with Lantheus shareholders receiving $102.50 per share in cash at closing, plus up to $12.00 per share in Contingent Value Rights (CVRs) tied to future commercial milestones. The merger is designed to strengthen innovation across oncology, neurology and cardiology, enabling the combined company to serve healthcare providers and patients in more than 70 countries while expanding access to advanced nuclear medicine solutions. The boards of both companies have approved the agreement, which remains subject to shareholder and regulatory approvals and is expected to close during the first half of 2027.
Strategic Merger Creates Global Radiopharmaceutical Leader
The merger combines two established innovators with complementary strengths across the nuclear medicine value chain. Curium has built a strong global presence through its expertise in the development, manufacturing and supply of diagnostic and therapeutic radiopharmaceuticals, while Lantheus has established itself as a leading U.S. radiopharmaceutical company with successful diagnostic products spanning prostate cancer imaging, neurology and cardiovascular imaging. Together, the organizations aim to deliver an integrated platform covering isotope production, radiopharmaceutical manufacturing, diagnostic imaging and targeted radionuclide therapies, creating one of the industry’s most comprehensive portfolios. According to the companies, the transaction accelerates Curium’s strategy to expand its theranostics platform, strengthens its U.S. commercial infrastructure and provides entry into additional diagnostic markets including neurology and echocardiography. Lantheus’ board unanimously concluded that the agreement provides the strongest long-term value for shareholders following a comprehensive review of strategic alternatives.
Transaction Strengthens Theranostics and Commercial Growth
Under the definitive agreement, Curium will acquire all outstanding Lantheus shares through a combination of cash consideration and milestone-based CVRs, with total potential shareholder value reaching $114.50 per share. The CVRs are linked to future commercial performance across key franchises including global prostate cancer diagnostics, neurology diagnostics and the DEFINITY® business, providing additional upside if specified revenue milestones are achieved through 2030. The acquisition will be financed through a combination of debt and equity and is not subject to financing contingencies. Until completion of the transaction, Lantheus will continue operating as an independent publicly traded company. The merger also brings together Curium’s extensive global manufacturing network of more than 80 manufacturing sites, a portfolio of over 45 radiopharmaceutical products, and Lantheus’ long-standing expertise in commercializing innovative imaging agents, creating a stronger platform for accelerating precision diagnostics and targeted cancer therapies worldwide.
Advertisement
Combined Company Expands Innovation Across Nuclear Medicine
The proposed merger reflects the increasing importance of radiopharmaceuticals in modern precision medicine and cancer care. Curium has continued expanding its radioligand therapy pipeline while investing in manufacturing infrastructure to support growing global demand for theranostic solutions. Lantheus has played a pivotal role in advancing PSMA PET imaging, cardiac ultrasound enhancement and neurological imaging over several decades, making it a complementary strategic partner. By combining research capabilities, commercial expertise and manufacturing capacity, the merged organization is expected to accelerate development and commercialization of next-generation diagnostic and therapeutic radiopharmaceuticals for oncology, neurology and cardiology. The companies believe the transaction will enable broader patient access to innovative nuclear medicine technologies while strengthening long-term investment in precision imaging and targeted treatment platforms that continue transforming the diagnosis and management of complex diseases worldwide.
Source: Curium, Lantheus press release
